PresentationWilliam SzablewskiHead of Investor Relations & Capital Markets Good morning, everyone, and welcome to our Viatris Investor event. I'm Bill Szablewski, Head of Capital Markets and Investor Relations. It's great to see everyone here in a full room today. Before we begin, a few comments on our forward-looking and disclaimer. During today's discussion, we will be making forward-looking statements on a number of matters, including our strategic initiatives and priorities, pipeline, products and long ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

RARE Deadline: RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit Accessibility StatementSkip NavigationNEW YORK, March 25, 2026 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline.So what: If you purchased Ultragenyx common stock ...

CALGARY, Alberta, March 25, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that the Company’s board of directors has approved consolidating (the “Consolidation”) its common shares (“Shares”) on the basis of one post-consolidation Share for every five pre-consolidation Shares, effective March ...

NEW YORK, March 25, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 through November 4, 2025, both dates inclusive (the “Class Period”), of the important May 5, 2026 lead plaintiff deadline. SO WHAT: If you purchased Soleno common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee ar ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Inovio (INO) To Contact Him Directly To Discuss Their Options If you purchased or acquired Inovio securities between October 10, 2023 and December 26, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648. Click here to participate in the action. NEW YORK, March 25, 2026 (GLOBE NEWSWIRE) -- What’s Happening: ...

Cardiff Oncology (NasdaqCM:CRDF) Update / briefing March 25, 2026 04:30 PM ET Company ParticipantsHeinz-Josef Lenz - University Professor of Medicine, Preventive Medicine, and Cancer BiologyMani Mohindru - Interim CEOScott Kopetz - Professor and Deputy Chair in the Department of Gastrointestinal Medical OncologyConference Call ParticipantsMarc Frahm - Managing Director and Senior Research AnalystMaury Raycroft - Equity Research AnalystModeratorPlease be advised that today's conference is being recorded. I w ...

The Dow Jones Industrial Average (^DJI) was up 305.43 (+0.66%) points today, closing at 46,429.49. Dow Futures (YM=F) also signaled strength, rising 280.00 (+0.60%) points to reach 46,695.00. The primary driver for Wednesday’s market action was a better-than-expected Durable Goods report, which suggested that capital spending remains resilient despite elevated borrowing costs. This economic data sparked a rally in cyclical stocks, as investors gained confidence in a "soft landing" scenario for the U.S. econ ...

At Friedrich Global Research , we are searching for what we believe will be the safest and best-performing companies in which to buy stocks. We focus on free cash flow, efficient capital allocation, and consistently superior results to identify the highest quality management teams.I like dividend-paying stocks that have a history of raising the dividend consistently, year after year. I also like finding stocks that are currently out of favor, either due to macro events or temporary (but reversible) mistakes ...

Advances Clinical Pipeline Across Dermatology, Urology, Oncology and strengthens Capital Base to support Phase 2 Programs PHILADELPHIA, PA / ACCESS Newswire / March 25, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today reported audited financial results for the year ended December 31, 2025, and provided a corporate update highlighting sign ...